Metastasis to the occipitocervical junction: A case report and review of the literature

Risheng Xu1,2,3, Daniel M. Sciubba2,3, Ziya L. Gokaslan2,3, Ali Bydon2,3

1Medical Scientist Training Program, Johns Hopkins School of Medicine, Baltimore, Maryland, 2Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, Maryland, 3Johns Hopkins Spinal Column Biomechanics and Surgical Outcomes Laboratory, Baltimore, Maryland

E-mail: Risheng Xu - rxu4@jhmi.edu; Daniel M. Sciubba - dsciubb1@jhmi.edu; Ziya L. Gokaslan - zgokasl1@jhmi.edu; *Ali Bydon - abydon1@jhmi.edu

*Corresponding author

INTRODUCTION

Lung cancer is classified by the World Health Organization as the leading cause of cancer-related deaths in men and the second highest in women, claiming more than 1.2 million lives worldwide per year. In the United States alone, nearly 215,000 new cases of lung cancer will be diagnosed this year; 161,000 will succumb to the disease. This translates to lung cancer accounting for almost 30% of all cancer mortality in the United States, more than breast, prostate, and colon cancer combined. Of all lung cancers—diagnosed via histopathological criteria—non-small-cell (NSCLC) type accounts for approximately 80% of all primary lung tumors.

The prognosis of patients diagnosed with lung cancer is poor, due to association with systemic, incurable disease. As of 2005, although the average age of presentation of newly diagnosed patients increased to approximately 68 years, 65% were initially diagnosed with Stage IIIIB or IV disease, with a median survival rate of four to six months.
Less than 20% of patients remained alive at one year. NSCLC metastasizes to a variety of locations within the body, including the brain, bone, liver, and adrenal glands, in order of decreasing prevalence. Of note, the skeleton is a particularly common site of metastasis, with most recent retrospective studies estimating the incidence of NSCLC skeletal metastases to be 24% in American populations, and as high as 30% among the Japanese. Although NSCLC appears to metastasize most frequently to the axial skeleton, the involvement of the craniovertebral junction is far rarer.

In this report, we present a patient with known NSCLC metastasis who presented with severe axial neck pain due to tumor infiltration and destruction of the atlanto-occipital joint. Although the etiologies and treatment strategies for managing destructive lesions of the atlantoaxial (C1-C2) joint are known, to our knowledge, this is the first published case of an NSCLC lesion that metastasized to both the occipital condyle and the atlas (atlanto-occipital joint), causing instability and severe neck pain. We also review the literature and discuss current treatment options for bony metastasis to the occipitocervical junction.

**CLINICAL SUMMARY**

A 66-year-old female with a two-year history of NSCLC status post lobectomy, with metastasis to the right kidney, right femur and pelvis, presented with severe occipital headaches and debilitating neck pain. She was functionally independent, with a Karnofsky score of 90. She was neurologically intact except for a left homonymous hemianopsia due to an old posterior cerebral artery distribution infarct. Brain and cervical spine computed tomography (CT) and magnetic resonance imaging (MRI) scans revealed an old right occipital stroke, right C1 lateral mass and occipital condyle destructive lytic lesions, and a fracture of the right atlanto-occipital joint [Figure 1a-c]. There was no evidence of spinal cord compression [Figure 1d]. She had difficulty sitting up or standing up due to severe axial neck pain. She was started on intravenous morphine and placed in a cervical collar, which improved her pain minimally. Due to the destruction of the joint evident on radiographic images and the partial relief of the pain after stabilizing her in a neck orthosis, it was thought that the patient would benefit from internal stabilization.

The patient underwent an occiput to C5 instrumented stabilization and fusion using an occipital plate connected to lateral mass screws at C3, C4, and C5 [Figures 2 and 3]. Demineralized bone matrix (Optium, DePuy, Johnson and Johnson), mixed with cancellous bone chips were placed over the arthrodosed lamina and joints. Postoperatively, she experienced substantial neck pain relief, and was discharged in stable neurologic condition. She remained independently ambulatory and resided with her family. At her most recent follow-up (12 months postoperatively), the patient exhibited a neck pain level of 2/10, demonstrating sustained pain relief. A lateral cervical spine X-ray revealed no evidence of hardware failure or kyphosis [Figure 4]. The patient succumbed to her metastatic disease 14 months postoperatively.

**DISCUSSION**

Distant bony metastases of lung cancer have been...
associated with significant skeletal-related events (SREs), including pain (secondary to either tumor infiltration or ensuing mechanical instability), pathological fractures, hypercalcemia, and spinal cord compression. Of these comorbidities, bone pain is the most common, seen in 80% of patients with skeletal NSCLC metastases. Other SREs such as fractures and hypercalcemia owe their pathophysiology primarily to the tumor-induced increase of osteoclast differentiation relative to osteoblasts. Nevertheless, despite the prevalence of skeletal metastases—with the spine, ribs, and pelvis being the most common—encroachment upon the occipital condyle and atlas is exceedingly rare. Within the English literature (PubMed/Medline), no case of NSCLC metastasis to the occipitocervical junction has been previously described.

Metastatic involvement of the craniovertebral junction due to other primary tumors has been described in seven cases with documentation of involvement of the C0-C1 junction and ensuing instability [Table 1]. Specifically, George et al. reported four cases of metastatic cancer involving the atlanto-occipital joint over a 20-year period from 1981-2001. In a case report, Akai et al. described a patient with malignant fibrous histiocytoma invasion of the right craniovertebral junction who presented with intractable occipitalgia. Elia et al. described a patient with C0-C1 instability due to myeloma, and Laohacharoensombat et al. described a case of metastatic follicular thyroid cancer to the occipitocervical region. Thus, to our knowledge, this is the first reported case in the English literature of NSCLC metastasis to the craniovertebral junction causing instability of the occipito-atlantal joint and subsequent severe axial neck pain.

Given the poor prognosis of metastatic spine disease, especially late-stage NSCLC, treatment for such lesions are palliative in nature. Well-defined NSCLC lesions may be treated with radiotherapy and/or surgery. Specifically, surgical intervention is generally indicated for patients with symptomatic epidural spinal cord compression, spinal column instability leading to pain or neurological deficits, or radio-resistant tumors in patients with life expectancies of at least six months duration. Concurrent systemic disease is simultaneously treated with chemotherapeutic agents, hormonal therapy, bisphosphonates, and radionucleotides. Although double-regimen, platinum-based chemotherapeutics are the standard of care for treating advanced NSCLC, recent Phase III clinical trials are still establishing the efficacies of new multimodal agents based on novel cytotoxic and target-based therapeutics. In addition, current Phase II clinical trials utilizing monoclonal antibodies to inhibit osteoclast function have revealed promising data as an alternative method to suppressing osteoclast activity in mediating bone loss/resorption and hypercalcemia compared with bisphosphonates, currently considered the standard of care. Although survival of patients with metastatic spinal disease ultimately depends on the extent and control of the underlying systemic disease, quality of life can be substantially improved with surgical stabilization. In their landmark study, Patchel et al. concluded that direct surgical decompression plus radiation therapy for metastatic epidural spinal cord compression improved functional status, relative to ambulation and continence, compared to radiation alone. Although some patients in that series suffered neurological decline secondary...
to spinal cord compression, we believe it is likely that surgical stabilization also contributed substantially to the improvement in postoperative ambulation due to the treatment of mechanical instability and its associated pain. In our patient, such mechanical pain was drastically improved with minimal surgical morbidity. Of note, although sectioning of the C2 nerve roots may be an effective method for controlling pain in patients with C2 neuralgia, it was felt that in this patient’s case her debilitating neck pain was due mainly to the destruction of her atlanto-occipital joint; thus, open C2 rhizotomy was not performed. In reviewing the seven other published cases of metastatic disease to the occipitocervical junction, all treatments have also consisted of occipitocervical fusion, coupled with tumor resection, radiation, and/or chemotherapy. In most cases, patients with metastatic disease at the atlanto-occipital joint experience a reduction in headache or upper neck pain following occipitocervical fusion. However, it was noted that preoperative motor loss and cranial nerve deficits such as swallowing difficulties or hoarseness were not restored postoperatively. As a result, in those patients with significant preoperative neurological deficits in addition to mechanical pain, expectations following surgical treatment should be carefully addressed with patients with regards to likelihood of improved neurological function. Currently in the United States, the general practice is to offer occipitocervical fixation to patients with a life expectancy greater than three to six months. As healthcare policies in the United States continue to evolve, it is hoped that the decision on whether to pursue an operative fusion procedure in the face of metastatic disease will remain a choice made jointly by the patient, his/her treating oncologist and neurosurgeon.

### Table 1. Summary of other metastatic occipitocervical tumors, their treatments, and their post-operative outcomes

| Reference          | Year | Sex | Age | Indication for Operation                                      | Pathology                              | Treatment                                                                 | Outcome at Last Followup                                                                 |
|--------------------|------|-----|-----|----------------------------------------------------------------|----------------------------------------|----------------------------------------------------------------------------|------------------------------------------------------------------------------------------|
| Elia et al         | 1990 | F   | 70  | C0-C1 instability                                              | Myeloma                                | C0-C4 Fusion using the Onlay technique                                      | Fused at 16 weeks                                                                        |
| Laohacharoensombat et al | 1990 | F   | 43  | Neck pain and radiculopathy; tumor invasion of foramen magnum with atlanto-occipital subluxation; C3, C5 tumor invasion | Follicular thyroid carcinoma            | C0-C7 fusion using an occipital pin with additional cement reinforcement      | Neck stiffness, ambulation restored, lost to follow up at 2-3 months                      |
| Akai et al         | 2006 | F   | 59  | Severe occipitalgia, right C0-C1 joint destruction              | Malignant fibrous histiocytoma          | Partial tumor resection, occipitocervical fusion with the Olerud Cervical Fixation System, post-operative radiation therapy and chemotherapy | Resolution of headaches; tumor recurrence followed by resection two additional times; patient became paraplegic and died of respiratory failure; 2 years and 4 months total treatment course |
| George et al       | 2006 | F   | 46  | Upper neck pain, C0-C1 tumor invasion, lateral condyle destruction | Melanoma                                | Lateral approach, occipitocervical fusion with plates and bone graft         | Fusion achieved, significant pain resolution                                               |
| George et al       | 2006 | M   | 57  | Upper neck pain, C0-C1 tumor invasion, lateral condyle destruction | Thyroid                                 | Tumor embolization, lateral approach, occipitocervical fusion with plates and bone graft | Fusion achieved, significant pain resolution                                               |
| George et al       | 2006 | M   | 63  | Upper neck pain, C0-C1 tumor invasion, lateral condyle destruction, tetraplegia | Lung (pathology unknown)               | Lateral approach, occipitocervical fusion with plates and bone graft         | Respiratory failure due to extensive metastasis leading to death                         |
| George et al       | 2006 | M   | 61  | Upper neck pain, C0-C1 tumor invasion, lateral condyle destruction | Thyroid                                 | Tumor embolization, lateral approach, occipitocervical fusion with plates and bone graft | Fusion achieved, significant pain resolution                                               |
CONCLUSIONS

This is the first reported case of NSCLC metastasizing to the atlanto-occipital joint causing severe sudden onset neck pain due to mechanical instability. Significant alleviation of pain was achieved via surgical stabilization (occipitocervical fusion). Although metastatic disease caused by NSCLC carries a poor prognosis, occipitocervical stabilization may provide excellent pain relief and improvements in quality of life in properly selected patients.

REFERENCES

1. Aebi M. Spinal metastasis in the elderly. Eur Spine J 2003;12:S202-13.
2. Akai T, Yamanoto K, Iida T, Iizuka H, Nojima T. Malignant fibrous histiocytoma in the craniofacial junction presenting with severe occipitalgia. Brain Tumor Pathol 2006;23:101-5.
3. Bezjak A. Palliative therapy for lung cancer. Semin Surg Oncol 2003;21:138-47.
4. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s.
5. Delbaldo C, Michiels S, Rolland E, Syz N, Soria JC, Le Chevalier T, et al. Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease. Cochrane Database Syst Rev 2007;4:CD004569.
6. Edelman MJ, Khanwani SL. Advanced non-small cell lung cancer. Curr Treat Options Oncol 2001;2:51-62.
7. Elia M, Mazzara JT, Fielding JW. Onlay technique for occipitocervical fusion. Clin Orthop Relat Res 1992;280:170-4.
8. Fournier PG, Chirgwin JM, Guise TA. New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol 2006;18:396-404.
9. George B, Archilli M, Cornelius JF. Bone tumors at the cranio-cervical junction. Surgical management and results from a series of 41 cases. Acta Neurochir (Wien) 2006;148:741-9.
10. Ginsberg MS, Grewal RK, Heelan RT. Lung cancer. Radiol Clin North Am 2007;45:21-43.
11. Kingsley LA, Fournier PG, Chirgwin JM, Guise TA. Molecular biology of bone metastasis. Mol Cancer Ther 2007;6:2609-17.
12. Kosteva JL, Langer C. The changing landscape of the medical management of skeletal metastases in nonsmall cell lung cancer. Curr Opin Oncol 2008;20:155-61.
13. Kosteva JL. Incidence and distribution of skeletal metastases in NSCLC in the era of PET. Lung Cancer 2004;46:545.
14. Laohacharoenombat W, Suphachatwong C. Occipital pin for rigid occipitocervical fixation in upper cervical metastasis. Bull Hosp J Dis Orthop Inst 1990;50:20-6.
15. Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-7.
16. Nagel S, Califano R, Thatcher N, Blackhall F. Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. Expert Opin Pharmacother 2007;8:3265-75.
17. Pandit-Taskar N, Batra K, Divgi CR. Radiotherapeutic therapy for palliation of bone pain from osseous metastases. JNucl Med 2004;45:1358-65.
18. Patchell RA, Tibbs PA, Regine WF, Payne R, Saris S, Kryscio RJ, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005;366:643-8.
19. Quint LE, Tummla S, Brisson LJ, Francis IR, Krupnick AS, Kazerouni EA, et al. Distribution of distant metastases from newly diagnosed non-small cell lung cancer. Ann Thorac Surg 1996;62:246-50.
20. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 2008;13:3-13.
21. Society AC. Cancer facts and figures. Available from: http://www.cancer.org/docroot/STT/content/STT_1x_cancer_facts_and_figures_2008.asp. [cited in 2008].
22. Spiro SG, Silvestri GA. The treatment of advanced non-small cell lung cancer. Curr Opin Pulm Med 2005;11:287-91.
23. Stinchcombe TE, Socinski MA. Considerations for second-line therapy of non-small cell lung cancer. Oncologist 2008;13:28-36.
24. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75:191-202.
25. Tsuya A, Kurata T, Tamura K, Fukuoka M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 2007;57:229-32.
26. WHO. The World Health Report 2004: Changing History. 2004. p. 122-3.